2. Academic Validation
  3. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro

Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro

  • Front Microbiol. 2021 Apr 30;12:651403. doi: 10.3389/fmicb.2021.651403.
Kaho Shionoya 1 2,  Masako Yamasaki 1 2,  Shoya Iwanami 3 4,  Yusuke Ito 4,  Shuetsu Fukushi 5,  Hirofumi Ohashi 1 2,  Wakana Saso 1 6 7,  Tomohiro Tanaka 8,  Shin Aoki 9,  Kouji Kuramochi 2,  Shingo Iwami 3 4 10 11 12 13 14,  Yoshimasa Takahashi 15 16,  Tadaki Suzuki 17,  Masamichi Muramatsu 1,  Makoto Takeda 18,  Takaji Wakita 1,  Koichi Watashi 1 2 10 16 19
Affiliations

Affiliations

  • 1 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
  • 2 Department of Applied Biological Science, Tokyo University of Science, Tokyo, Japan.
  • 3 Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • 4 Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan.
  • 5 Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
  • 6 The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • 7 AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
  • 8 Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
  • 9 Research Institute for Science and Technology, Tokyo University of Science, Tokyo, Japan.
  • 10 MIRAI, JST, Saitama, Japan.
  • 11 Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan.
  • 12 Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan.
  • 13 NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
  • 14 Science Groove Inc., Fukuoka, Japan.
  • 15 Department of Immunology, National Institute of Infectious Diseases, Tokyo, Japan.
  • 16 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
  • 17 Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • 18 Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.
  • 19 Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
PMID: 33995308 DOI: 10.3389/fmicb.2021.651403
Abstract

Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the Infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher Antiviral potency, we screened approved Anti-parasitic/anti-protozoal drugs and identified an anti-malarial drug, Mefloquine, which showed the highest anti-SARS-CoV-2 activity among the tested compounds. Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 μM, IC90 = 2.31 μM, and IC99 = 4.39 μM in VeroE6/TMPRSS2 cells. Mefloquine inhibited viral entry after viral attachment to the target cell. Combined treatment with Mefloquine and Nelfinavir, a replication inhibitor, showed synergistic Antiviral activity. Our mathematical modeling based on the drug concentration in the lung predicted that Mefloquine administration at a standard treatment dosage could decline viral dynamics in patients, reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.1 days. These data cumulatively underscore Mefloquine as an anti-SARS-CoV-2 entry inhibitor.

Keywords

COVID-19; SARS-CoV-2; coronavirus; malaria; mefloquine; repurposing; severe acute respiratory syndrome-related coronavirus 2.

Figures
Products